Recurrent Gastric Cancer Clinical Trial
— 3GOfficial title:
A Phase II Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients
This is an open, non-randomized, multicenter Phase II study evaluating cisplatin plus TS-1
or oxaliplatin plus TS-1 as first-line therapy in predicted 'responder' to platinum and
fluoropyrimidine.
This study is planned in 3 centers in Singapore and Korea. A total of 30 subjects will be
enrolled into each treatment arms. Each centers will recruit 15-25 subjects predicted to be
'responder' to platinum and fluoropyrimidine. The study will consist of a prescreening
period, a screening period and a treatment period. A fresh tumour biopsy sample will be
obtained during the prescreening period for gene expression profiling.
As this is a genomics guided trial, obtaining tissue biopsies is vital to the conduct of the
trial.
Patients will have the primary in situ (requirement for entry into trial), endoscopic biopsy
performed prior to 1st cycle.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | December 2018 |
Est. primary completion date | December 2017 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years to 99 Years |
Eligibility |
Inclusion Criteria: - Histologically or cytologically documented locally advanced, metastatic or recurrent gastric cancer for which convention therapy of a platinum/fluoropyrimidine combination is indicated - Predicted 'responder' to platinum and fluoropyrimidine based on tumour expression signature derived from in-vitro sensitivity array - At least one measurable defined by RECIST - Age >=21 years old - Performance status (ECOG) 0-2 - Life expectancy >3 months - No significant problems for oral intake and drug administration - Adequate organ functions: bone marrow function (ANC = 1,500/uL, Platelet = 100,000/ uL, Hb = 8.0 g/dl) renal function: serum creatinine = UNL (if serum creatinine > ULN, creatinine clearance should be = 60 mL/min) hepatic function (Total bilirubin < 2 x UNL and AST/ALT levels < 3 x ULN without liver metastasis, total bilirubin < 3x ULN and AST/ALT levels < 5 x ULN with liver metastasis) - Recovery from relevant toxicity to previous treatment before study entry - Ability to understand and willingness to sign a written informed consent before study entry Exclusion Criteria: - Prior chemotherapy for gastric cancer except neoadjuvant or adjuvant systemic therapy if terminated at least 6 months before the start of treatment in this study - Prior radiotherapy was administered to target lesions selected for this study - Second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than 5 years ago without recurrence) - Presence of symptomatic or progressing CNS metastasis - Serious illness or medical conditions: Congestive heart failure (NYHA class III or IV), unstable angina or myocardial infarction within the past 3 months Hepatic cirrhosis (= Child class B) Psychiatric disorder that may interfere with protocol compliance Active infection - Known hypersensitivity to platinum or fluoropyrimidine. - Pregnant or lactating woman. Women of child bearing potential not using a contraceptive method - Sexually active fertile men not using effective birth control during medication of study drug and up to 6 months after completion of study drug if their partners are women of child-bearing potential - Any patients judged by the investigator to be unfit to participate in the study - Predicted 'non-responder' to platinum and fluoropyrimidine based on tumour expression signature derived from in- vitro sensitivity array |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Singapore | National University Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
National University Hospital, Singapore | National Cancer Centre, Singapore, Yonsei University |
Singapore,
Arai W, Hosoya Y, Hyodo M, Yokoyama T, Hirashima Y, Yasuda Y, Nagai H, Shirasaka T. Alternate-day oral therapy with TS-1 for advanced gastric cancer. Int J Clin Oncol. 2004 Jun;9(3):143-8. — View Citation
Koizumi W. Chemotherapy for advanced gastric cancer: review of global and Japanese status. Gastrointest Cancer Res. 2007 Sep;1(5):197-203. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response Rate (RR) | To determine the response rate of cisplatin/TS-1 and oxaliplatin/TS-1 combination in predicted 'responders' | 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT00982592 -
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
Completed |
NCT00991952 -
Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT00098527 -
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
Terminated |
NCT01249443 -
Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
|
Phase 1 | |
Completed |
NCT01612546 -
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT00028535 -
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT01939275 -
64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer
|
N/A | |
Unknown status |
NCT01491217 -
A Study of Oraxol® in Gastric Cancer Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
Completed |
NCT00084617 -
Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
|
Phase 2 | |
Completed |
NCT00068380 -
A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
|
Phase 2 | |
Terminated |
NCT00064259 -
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00089362 -
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
|
Phase 1 | |
Completed |
NCT03602079 -
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
Phase 1/Phase 2 | |
Completed |
NCT00607594 -
Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
|
Phase 2 |